Antiphospholipid syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
Feham Tariq (talk | contribs) |
Feham Tariq (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Primary Prevention== | ==Primary Prevention== | ||
The primary prevention of antiphospholipid syndrome is as follows:<ref name="pmid24449256">{{cite journal| author=Nalli C, Andreoli L, Casu C, Tincani A| title=Management of recurrent thrombosis in antiphospholipid syndrome. | journal=Curr Rheumatol Rep | year= 2014 | volume= 16 | issue= 3 | pages= 405 | pmid=24449256 | doi=10.1007/s11926-013-0405-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24449256 }} </ref> | The primary prevention of antiphospholipid syndrome is as follows:<ref name="pmid24449256">{{cite journal| author=Nalli C, Andreoli L, Casu C, Tincani A| title=Management of recurrent thrombosis in antiphospholipid syndrome. | journal=Curr Rheumatol Rep | year= 2014 | volume= 16 | issue= 3 | pages= 405 | pmid=24449256 | doi=10.1007/s11926-013-0405-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24449256 }} </ref><ref name="pmid15507275">{{cite journal| author=Erkan D, Lockshin MD| title=How much warfarin is enough in APS related thrombosis? | journal=Thromb Res | year= 2004 | volume= 114 | issue= 5-6 | pages= 435-42 | pmid=15507275 | doi=10.1016/j.thromres.2004.06.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15507275 }} </ref> | ||
* Anticoagulation in patients with risk factors for arterial and venous thrombosis. | * Anticoagulation in patients with risk factors for arterial and venous thrombosis. | ||
* Minimizing the contribution of reversible risk factors for recurrent thrombosis. | * Minimizing the contribution of reversible risk factors for recurrent thrombosis. | ||
Revision as of 18:45, 11 April 2018
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention |
|
Risk calculators and risk factors for Antiphospholipid syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Primary Prevention
The primary prevention of antiphospholipid syndrome is as follows:[1][2]
- Anticoagulation in patients with risk factors for arterial and venous thrombosis.
- Minimizing the contribution of reversible risk factors for recurrent thrombosis.
- A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.
References
- ↑ Nalli C, Andreoli L, Casu C, Tincani A (2014). "Management of recurrent thrombosis in antiphospholipid syndrome". Curr Rheumatol Rep. 16 (3): 405. doi:10.1007/s11926-013-0405-4. PMID 24449256.
- ↑ Erkan D, Lockshin MD (2004). "How much warfarin is enough in APS related thrombosis?". Thromb Res. 114 (5–6): 435–42. doi:10.1016/j.thromres.2004.06.010. PMID 15507275.